Led by Bayer Healthcare, the first Phase 3 trial VIVID-DME, in DME is also expected to be organized in Europe and Japan.
However, the second trial will be led by Regeneron in the US, Canada, and other countries, and is expected to be start in late 2011.
Bayer HealthCare Executive Committee Global Development head Kemal Malik said after reporting positive results from the global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age-related macular degeneration (wet AMD), they are pleased to start a Phase 3 program with VEGF Trap-Eye in DME which may help to address this significant unmet medical need.